<DOC>
	<DOC>NCT01084876</DOC>
	<brief_summary>The purpose of the study is to to demonstrate equivalence</brief_summary>
	<brief_title>Demonstrate Efficacy and Safety of Metastatic Breast Cancer</brief_title>
	<detailed_description>Patients will receive study drug every 3 weeks.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Are females Have a Her 2 overexpression Have ECOG 0 or 1 Current clinical or radiographic evidence CNS metastases Current Known infection Pregnant or nursing mother</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Herceptin</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>CT-P6</keyword>
</DOC>